

Educational Sessions

Wednesday, 11 September 2019

08.00 – 09.30	Educational Session	Hall C
	Educational Session 1 (MAGNIMS): Update on MAGNIMS guidelines on the use of MRI in the diagnosis and monitoring of multiple sclerosis	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>A. Rovira (Barcelona, ES)</i>	
08.00	How and when to obtain brain MRI in the diagnosis and monitoring of multiple sclerosis?	
	<i>M. Wattjes (Hannover, DE)</i>	
08.30	Value of spinal cord MRI	
	<i>O. Ciccarelli (London, UK)</i>	
09.00	When and how to use gadolinium?	
	<i>A. Rovira (Barcelona, ES)</i>	

08.00 – 09.30	Educational Session	Hall D
	Educational Session 2: Paediatric MS	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>R. Hintzen (Rotterdam, NL)</i>	
	<i>J. Gärtner (Göttingen, DE)</i>	
08.00	How to prevent secondary progression in children with MS	
	<i>J. Gärtner (Göttingen, DE)</i>	
08.30	The management of anti-MOG positive ADS	
	<i>R. Hintzen (Rotterdam, NL)</i>	
09.00	Differential diagnosis	
	<i>C. Hemingway (London, UK)</i>	

08.00 – 09.30	Educational Session	Hall F
	Educational Session 3: B cell therapy of MS – pathology, immunology, clinical effects	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>C. Stadelmann (Göttingen, DE)</i>	
	<i>K. Schmierer (London, UK)</i>	
08.00	Insights from pathology underpinning B cell-targeted therapy	
	<i>C. Stadelmann (Göttingen, DE)</i>	
08.30	Are B cells all that matters?	
	<i>D. Baker (London, UK)</i>	
09.00	Relapses, inflammation, progression: Mind our life-changing language	
	<i>K. Schmierer (London, UK)</i>	

08.00 – 09.30	Educational Session	Hall G
	Educational Session 4: Disease modifying treatments in MS	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>A. Green (San Francisco, US)</i>	
08.00	Details to be announced	

08.00 – 09.30	Educational Session	Hall H
	Educational Session 5 (RIMS): Rehabilitation in progressive MS	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>J. Freeman (Plymouth, UK)</i>	
	<i>P.L. Eelen (Melsbroek, BE)</i>	
08.00	Rehabilitaiton approaches in progressive MS	
	<i>J. Freeman (Plymouth, UK)</i>	
08.30	Bladder and bowel in progressive MS	
	<i>P.L. Eelen (Melsbroek, BE)</i>	
09.00	Caregiver burden in progressive MS	
	<i>V. Matthews (Herts, UK)</i>	

09.45 – 10.30	Educational Session	Meeting room T3
	Case-based Educational Session 6: How to manage urogenital problems and spasticity	
	Chairs:	
	<i>P. Flachenecker (Bad Wildbad, DE)</i>	
	<i>I. Kleiter (Berg, DE)</i>	
09.45	Case #1: Multimodal management of spasticity	
	<i>P. Flachenecker (Bad Wildbad, DE)</i>	
10.05	Case #2: Diagnosis and therapy of voiding difficulties	
	<i>I. Kleiter (Berg, DE)</i>	

09.45 – 10.30	Educational Session	Meeting room T4
	Case-based Educational Session 7: How to manage non response to induction therapies?	
	Chairs:	
	<i>A.J. Coles (Cambridge, UK)</i>	
	<i>J. Sastre-Garriga (Barcelona, ES)</i>	
09.45	Case #1	
	<i>A.J. Coles (Cambridge, UK)</i>	
10.05	Case #2	
	<i>J. Sastre-Garriga (Barcelona, ES)</i>	

09.45 – 10.30	Educational Session	Meeting room T5
	Case-based Educational Session 8: Progressive MS: who should be treated and what should patients expect?	
	Chairs:	
	<i>J. Chataway (London, UK)</i>	
	<i>R.J. Fox (Cleveland, US)</i>	
09.45	Case #1	
	<i>J. Chataway (London, UK)</i>	
10.05	Case #2	
	<i>R.J. Fox (Cleveland, US)</i>	

13.45 – 15.15	Educational Session	Hall F
	Educational Session 9: Neurofilament light chains and other fluid biomarkers in MS	
	Level: Intermediate	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>J. Kuhle (Basel, CH)</i>	
	<i>F. Piehl (Stockholm, SE)</i>	
13.45	Setting the scene: the relevance of conventional CSF and imaging biomarkers in MS	
	<i>F. Piehl (Stockholm, SE)</i>	
14.15	Assay stability and preanalytics of neurofilament determinations.	
	<i>E. Willemse (Amsterdam, NL)</i>	
14.45	Blood neurofilament light chain: ready for the clinic?	
	<i>J. Kuhle (Basel, CH)</i>	

13.45 – 15.15	Educational Session	Hall G
	Educational Session 10: NMO-spectrum disorders: current concepts and clinical management	
	Level: Intermediate	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>J. Palace (Oxford, UK)</i>	
	<i>F. Paul (Berlin, DE)</i>	
13.45	NMOSD: an update	
	<i>J. Palace (Oxford, UK)</i>	
14.15	Making the diagnosis in challenging cases with case studies	
	<i>K. Fujihara (Sendai, JP)</i>	
14.45	Treatment challenges in NMOSD with case studies	
	<i>F. Paul (Berlin, DE)</i>	

- 13.45 – 15.15 Educational Session Hall H
- Educational Session 11: Getting it right – accurate diagnosis and avoiding misdiagnosis of MS**
- Level: Basic**
(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)
- Chairs:
G. Arrambide (Barcelona, ES)
W. Brownlee (London, UK)
- 13.45 **MS: What's typical, what's not?**
W. Brownlee (London, UK)
- 14.05 **Applying the 2017 McDonald criteria to make an accurate diagnosis**
G. Arrambide (Barcelona, ES)
- 14.25 **Tips for avoiding misdiagnosis**
A. Solomon (Burlington, US)
- 14.45 **Interactive case presentations for discussion**
G. Arrambide (Barcelona, ES)
W. Brownlee (London, UK)
A. Solomon (Burlington, US)
-
- 15.45 – 17.15 Educational Session Hall F
- Educational Session 12 (MAGNIMS): Big data and deep learning: new avenues for MRI research in MS?**
- Level: Advanced**
(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)
- Chairs:
M.A. Rocca (Milan, IT)
H. Vrenken (Amsterdam, NL)
- 15.45 **Big data in MRI research in MS**
M.A. Rocca (Milan, IT)
- 16.15 **Collaborative research environments and crowd-sourced science in MRI in MS**
H. Vrenken (Amsterdam, NL)
- 16.45 **Machine learning in MRI research in MS**
D. Pareto (Barcelona, ES)
-

15.45 – 17.15	Educational Session	Hall G
	Educational Session 13: Pregnancy management in MS	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>M.K. Houtchens (Brookline, US)</i>	
	<i>K. Hellwig (Bochum, DE)</i>	
15.45	Reproductive counseling in MS: guidance and guidelines in 2019	
	<i>M.K. Houtchens (Brookline, US)</i>	
16.15	Disease modifying medications in women with MS planning a pregnancy: 2019 update	
	<i>K. Hellwig (Bochum, DE)</i>	
16.45	Postpartum management in women with MS	
	<i>R. Bove (San Francisco, US)</i>	
<hr/>		
15.45 – 17.15	Educational Session	Hall H
	Educational Session 14: Diagnosis and management of other neuroinflammatory diseases (CLIPPERS, anti-GFAP, neurosarcoidosis, other systemic autoimmune diseases with CNS involvement)	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>D.M. Wingerchuk (Scottsdale, US)</i>	
	<i>E. Flanagan (Rochester, US)</i>	
15.45	Autoimmune GFAP astrocytopathy: characteristics and comparison to AQP4 and MOG-related disease	
	<i>E. Flanagan (Rochester, US)</i>	
16.15	Neurosarcoidosis, CNS vasculitis, and Behcet's disease	
	<i>J. Gelfand (San Francisco, US)</i>	
16.45	CLIPPERS and other rare CNS inflammatory syndromes	
	<i>D.M. Wingerchuk (Scottsdale, US)</i>	

Thursday, 12 September 2019

08.00 – 09.30	Educational Session	Hall E
	Educational Session 15: How do our treatments impact the immune system?	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>R. Liblau (Toulouse, FR)</i>	
	<i>L. Klotz (Münster, DE)</i>	
08.00	Impact of first-line MS treatments on the immune system	
	<i>L. Klotz (Münster, DE)</i>	
08.30	Migration-targeting therapies in MS: impact on immune responses	
	<i>R. Liblau (Toulouse, FR)</i>	
09.00	Cell-depleting strategies in MS: impact on immune responses	
	<i>A. Bar-Or (Philadelphia, US)</i>	

08.00 – 09.30	Educational Session	Hall F
	Educational Session 16 (IMSCOGS): Cognitive dysfunction in MS	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>R.H. Benedict (Buffalo, US)</i>	
	<i>M.P. Amato (Florence, IT)</i>	
08.00	Epidemiology and risk factors: an update	
	<i>M.P. Amato (Florence, IT)</i>	
08.30	How to diagnose and monitor in clinical practice	
	<i>R.H. Benedict (Buffalo, US)</i>	
09.00	How to manage: recent developments	
	<i>J. DeLuca (West Orange, US)</i>	

10.00 – 11.30	Educational Session	Hall E
	Educational Session 17: Pharmacovigilance and multiple sclerosis in the post-marketing setting: opportunity and lessons learned	
	Level: Advanced	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>H. Tremlett (Vancouver, CA)</i>	
	<i>M. Magyari (Copenhagen, DK)</i>	
10.00	Using linked health administrative and clinical data to investigate drug safety in MS	
	<i>H. Tremlett (Vancouver, CA)</i>	
10.30	Using registry data to investigate drug safety in MS	
	<i>M. Magyari (Copenhagen, DK)</i>	
11.00	Evolution of biological agents: how established drugs can become less safe	
	<i>D. Hunt (Edinburgh, UK)</i>	

10.00 – 11.30	Educational Session	Hall F
	Educational Session 18: Antibodies and Complement in MS Spectrum Disorders	
	Level: Intermediate	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>J. Bennet (Denver, US)</i>	
	<i>J. Lünemann (Münster, DE)</i>	
10.00	Antibody- and complement-mediated effector functions	
	<i>J. Lünemann (Münster, DE)</i>	
10.30	Antibody-mediated pathogenesis in central and peripheral neuroinflammatory disorders	
	<i>J. Bennet (Denver, US)</i>	
11.00	Therapeutic complement inhibition in neuroinflammatory diseases	
	<i>R. Mantegazza (Milan, IT)</i>	

11.45 – 12.45	Educational Session	Meeting room T3
	Case-based Educational Session 19: When to stop treatment?	
	Chairs: <i>G. Edan (Rennes, FR)</i> <i>E. Le Page (Rennes, FR)</i>	
11.45	Case #1: When to stop in relapsing remitting multiple sclerosis (RRMS) patient <i>E. Le Page (Rennes, FR)</i>	
12.15	Case #2: When to stop in stop in secondary progressive multiple sclerosis (SPMS) patient <i>G. Edan (Rennes, FR)</i>	
<hr/>		
14.15 – 15.45	Educational Session	Hall E
	Educational Session 20: Immunisation in MS	
	Level: Basic <i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs: <i>S. Vukusic (Lyon, FR)</i> <i>J. Correale (Buenos Aires, AR)</i>	
14.15	Vaccines and the risk of MS <i>J. Correale (Buenos Aires, AR)</i>	
14.45	Vaccines and the risk of relapses <i>J. Frederiksen (Copenhagen, DK)</i>	
15.15	Vaccines and DMTs <i>S. Vukusic (Lyon, FR)</i>	
<hr/>		
14.15 – 15.45	Educational Session	Hall F
	Educational Session 21: Comprehensive appraisal of MS studies	
	Level: Advanced <i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs: <i>M.P. Sormani (Genoa, IT)</i> <i>F. Deisenhammer (Innsbruck, AT)</i>	
14.15	How to assess and summarize study <i>E. Hernández Martínez-Lapiscina (Barcelona, ES)</i>	
14.45	Data analyses, interpretation, misinterpretation, and biases <i>M.P. Sormani (Genoa, IT)</i>	
15.15	Interpretation of analytical/deductive statistics <i>F. Deisenhammer (Innsbruck, AT)</i>	

- 16.15 – 17.15 Educational Session Meeting room T3
Case-based Educational Session 22 (RIMS): Progressive MS: losing mobility
Chairs:
V. de Groot (Amsterdam, NL)
A. Guldhammer Skjerbæk (Ry, DK)
- 16.15 **Diagnosing and treating gait problems using gait analysis**
V. de Groot (Amsterdam, NL)
- 16.35 **Ensuring an effective training to deal with mobility loss**
A. Guldhammer Skjerbæk (Ry, DK)

Friday, 13 September 2019

08.30 – 10.00	Educational Session	Hall E
	Educational Session 23: Radiologically Isolated Syndrome (RIS): incidental MRI findings or subclinical MS?	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>N. De Stefano (Siena, IT)</i>	
	<i>C. Lebrun (Nice, FR)</i>	
08.30	RIS: just incidental MRI findings or a real disease entity?	
	<i>D. Okuda (Dallas, US)</i>	
09.00	Can we diagnose subclinical MS?	
	<i>N. De Stefano (Siena, IT)</i>	
09.30	The management of RIS	
	<i>C. Lebrun (Nice, FR)</i>	

08.30 – 10.00	Educational Session	Hall F
	Educational Session 24: Pathology of MS	
	Level: Advanced	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>H. Lassmann (Wien, AT)</i>	
	<i>O. Howell (Swansee, UK)</i>	
08.30	The inflammatory response in the MS brain: implications for pathogenesis and therapy	
	<i>H. Lassmann (Wien, AT)</i>	
09.00	The spectrum of cortical pathology in the MS brain: when, where and why	
	<i>O. Howell (Swansee, UK)</i>	
09.30	Pathological correlates of 7T MRI: how far can we image MS pathology in the living patient	
	<i>S. Hametner (Vienna, AT)</i>	

10.30 – 12.00	Educational Session	Hall E
	Educational Session 25: Preventing, monitoring and managing infectious complications of MS therapies	
	Level: Basic	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>A. Vidal-Jordana (Barcelona, ES)</i>	
	<i>L. Prosperini (Rome, IT)</i>	
10.30	Prevention of infectious complications of MS therapies	
	<i>A. Vidal-Jordana (Barcelona, ES)</i>	
11.00	Monitoring MS therapies to rapidly detect infectious complications	
	<i>L. Prosperini (Rome, IT)</i>	
11.30	Managing infectious complications of MS therapies	
	<i>E. Ciampi (Santiago, CL)</i>	
<hr/>		
10.30 – 12.00	Educational Session	Hall F
	Educational Session 26: Which remyelination strategies are most promising?	
	Level: Advanced	
	<i>(Basic = neurologists in training, non MS-specialists / Intermediate = board examined neurologists / Advanced = MS specialists)</i>	
	Chairs:	
	<i>M. Simons (Munich, DE)</i>	
	<i>G. Castelo-Branco (Stockholm, SE)</i>	
10.30	Remyelination: insights from mouse models and transcriptomic studies	
	<i>G. Castelo-Branco (Stockholm, SE)</i>	
11.00	Remyelination: insights from human neuropathology	
	<i>C. Stadelmann (Göttingen, DE)</i>	
11.30	Remyelination: molecular mechanisms and therapeutic developments	
	<i>M. Simons (Munich, DE)</i>	